News

Our 5 experts return to examine the far-reaching repercussions of the COVID-19 pandemic on the physician burnout crisis.

Investigators added that the meta-analysis contributed to the comparative effectiveness literature for AGA therapies regarding the compared interventions.

Investigators observed significant increases in the rate of encounters with children and adolescents with autism spectrum disorder, as well as those with anxiety and depression.

Investigators noted that clinically relevant risks could not be excluded with certainty despite not seeing a statistically significant increase in corresponding risks for more rare and severe thrombotic outcomes.

The application for NVX-CoV2373 is supported by promising data from 2 multinational trials conducted prior to the spread of the Omicron variant.

New data show use exceeding the recommended daily dose for sleep aid has increased nearly 4-fold in the last 15 years.

Hospitals with lower-than-expected CDI antimicrobial use had on average fewer beds, shorter length of stay, and higher proportion of undergraduate or nonteaching medical school affiliation.

The study suggested children born extremely premature may remain "preterm for life," with ophthalmic sequelae persisting into adulthood.

New data from the NAVIGATOR study found that tezepelumab was associated with fewer asthma exacerbations throughout all seasons of the year compared to placebo.

The recombinant von Willebrand factor, VONVENDI, receives approval from the FDA to treat patients living with severe type 3 von Willebrand disease.

Resmetirom is being studied as a potential treatment for both NAFLD and NASH.

The approval of the Spikevax vaccine was based on safety and efficacy data approximately 6 months after the second dose.

Rates of aspirin use for preeclampsia prophylaxis were observed in a minority of women with risk factors including pre-pregnancy diabetes, obesity, or chronic hypertension.

A new assessment of payer incentives offered through physician organizations suggest the dominating emphasis of quantity over quality in pay.

Pfizer’s statement does not include a reason for the Complete Response Letter the FDA issued regarding the Biologics License Application for somatrogon for Pediatric Growth Hormone Deficiency.

The majority of drugs in development for IBD target inflammation.

Dr. Bagel details newer topical therapies such as tapinarof and roflumilast, and speaks to how greater access to these therapies is needed among psoriasis patients.

Though continuous positive airway pressure and high-flow nasal oxygen have both been recommended for acute hypoxemic respiratory failure in patients infected with the COVID-19 virus, the effectiveness and safety of these strategies were uncertain.

Don't Miss a Beat is Practical Cardiology's expert-led podcast. The monthly podcast, which is hosted by Drs. Greene and Vaduganathan, will provide a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases.

The Carter Center announces that just 14 cases of Guinea worm disease occurred worldwide in 2021--the lowest case total ever recorded.

About 30% of patients with ulcerative colitis do not adequately respond to anti-TNF therapy.

The findings of this study can be applied to guide opioid counseling and monitoring when prescribing the medication.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

A multitude of promising new investigative therapies are on the horizon for inherited retinal disease.

YOSEMITE and RHINE data further supports the novel agent for diabetic macular edema. A study investigators explains the impact of the new findings.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.